
[Federal Register Volume 79, Number 63 (Wednesday, April 2, 2014)]
[Notices]
[Pages 18561-18562]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07330]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2007-D-0369]


Draft and Revised Draft Guidances for Industry Describing 
Product-Specific Bioequivalence Recommendations; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
availability of additional draft and revised draft product-specific 
bioequivalence (BE) recommendations. The recommendations provide 
product-specific guidance on the design of BE studies to support 
abbreviated new drug applications (ANDAs). In the Federal Register of 
June 11, 2010, FDA announced the availability of a guidance for 
industry entitled ``Guidance for Industry on Bioequivalence 
Recommendations for Specific Products; Availability,'' which explained 
the process that would be used to make product-specific BE 
recommendations available to the public on FDA's Web site. The BE 
recommendations identified in this notice were developed using the 
process described in that guidance.

DATES: Although you can comment on any guidance at any time (see 21 CFR 
10.115(g)(5)), to ensure that the Agency considers your comments on 
these draft and revised draft guidances before it begins work on the 
final versions of the guidances, submit either electronic or written 
comments on the draft and revised draft product-specific BE 
recommendations listed in this notice by June 2, 2014.

ADDRESSES: Submit written requests for single copies of the individual 
BE guidances to the Division of Drug Information, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send 
one self-addressed adhesive label to assist that office in processing 
your requests. See the SUPPLEMENTARY INFORMATION section for electronic 
access to the draft guidance recommendations.
    Submit electronic comments on the draft product-specific BE 
recommendations to http://www.regulations.gov. Submit written comments 
to the Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Kris Andr[eacute], Center for Drug 
Evaluation and Research (HFD-600), Food and Drug Administration, 7520 
Standish Pl., Rockville, MD 20855, 240-276-8866.

SUPPLEMENTARY INFORMATION: 

I. Background

    In the Federal Register of June 11, 2010 (75 FR 33311), FDA 
announced the availability of a guidance for industry entitled 
``Guidance for Industry on Bioequivalence Recommendations for Specific 
Products; Availability,'' which explained the process that would be 
used to make product-specific BE recommendations available to the 
public on FDA's Web site at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
    As described in that guidance, FDA adopted this process as a means 
to develop and disseminate product-specific BE recommendations and 
provide a meaningful opportunity for the public to consider and comment 
on those recommendations. Under that

[[Page 18562]]

process, draft recommendations are posted on FDA's Web site and 
announced periodically in the Federal Register. The public is 
encouraged to submit comments on those recommendations within 60 days 
of their announcement in the Federal Register. FDA considers any 
comments received, and either publishes final recommendations or 
publishes revised draft recommendations for comment. Recommendations 
were last announced in the Federal Register on November 6, 2013 (78 FR 
66745). This notice announces draft product-specific recommendations, 
either new or revised, that are posted on FDA's Web site.

II. Drug Products for Which New Draft Product-Specific BE 
Recommendations Are Available

    FDA is announcing the availability of a new draft guidance for 
industry on product-specific BE recommendations for drug products 
containing the following active ingredients:

Table 1--New Draft Product-Specific BE Recommendations for Drug Products
------------------------------------------------------------------------
 
------------------------------------------------------------------------
A..............................  Amphotericin B.
                                 Atorvastatin calcium; Ezetimibe.
                                 Axitinib.
B..............................  Brinzolamide.
                                 Buprenorphine.
                                 Buprenorphine hydrochloride.
                                 Buprenorphine hydrochloride; Naloxone
                                  hydrochloride.
C..............................  Clobazam.
D..............................  Desoximetasone (multiple reference
                                  listed drugs and dosage forms).
                                 Diazoxide.
E..............................  Erythromycin.
                                 Estradiol.
F..............................  Fentanyl citrate.
G..............................  Guaifenesin.
H..............................  Hydrochlorothiazide; Metoprolol
                                  succinate.
L..............................  Levonorgestrel (multiple reference
                                  listed drugs).
                                 Linagliptin; Metformin hydrochloride.
M..............................  Mesalamine.
P..............................  Perampanel.
                                 Pindolol.
                                 Prednisolone acetate.
R..............................  Rabeprazole sodium.
T..............................  Teriflunomide.
                                 Tranylcypromine sulfate.
V..............................  Verteporfin.
------------------------------------------------------------------------

III. Drug Products for Which Revised Draft Product-Specific BE 
Recommendations Are Available

    FDA is announcing the availability of a revised draft guidance for 
industry on product-specific BE recommendations for drug products 
containing the following active ingredients:

   Table 2--Revised Draft Product-Specific BE Recommendations for Drug
                                Products
------------------------------------------------------------------------
 
------------------------------------------------------------------------
A..............................  Abiraterone acetate.
                                 Amlodipine besylate; Benazepril
                                  hydrochloride.
B..............................  Brimonidine tartrate (multiple
                                  reference listed drugs).
D..............................  Doxycycline hyclate.
                                 Dronabinol.
                                 Dutasteride; Tamsulosin hydrochloride.
I..............................  Icosapent Ethyl.
L..............................  Leuprolide acetate (multiple reference
                                  listed drugs and strengths).
M..............................  Metoprolol succinate.
                                 Morphine sulfate.
                                 Mycophenolate mofetil (multiple
                                  reference listed drugs and dosage
                                  forms).
                                 Mycophenolic acid.
N..............................  Naltrexone.
O..............................  Octreotide acetate.
T..............................  Trimethoprim.
                                 Triptorelin pamoate
------------------------------------------------------------------------

    For a complete history of previously published Federal Register 
notices related to product-specific BE recommendations, please go to 
http://www.regulations.gov and enter Docket No. FDA-2007-D-0369.
    These draft and revised draft guidances are being issued consistent 
with FDA's good guidance practices regulation (21 CFR 10.115). These 
guidances represent the Agency's current thinking on product-specific 
design of BE studies to support ANDAs. They do not create or confer any 
rights for or on any person and do not operate to bind FDA or the 
public. An alternative approach may be used if such approach satisfies 
the requirements of the applicable statutes and regulations.

IV. Comments

    Interested persons may submit either electronic comments on any of 
the specific BE recommendations posted on FDA's Web site to http://www.regulations.gov or written comments to the Division of Dockets 
Management (see ADDRESSES). It is only necessaary to send one set of 
comments. Identify comments with the docket number found in brackets in 
the heading of this document. The guidances, notices, and received 
comments may be seen in the Division of Dockets Management between 9 
a.m. and 4 p.m., Monday through Friday, and will be posted to the 
docket at http://www.regulations.gov.

V. Electronic Access

    Persons with access to the Internet may obtain the document at 
either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov.

    Dated: March 27, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-07330 Filed 4-1-14; 8:45 am]
BILLING CODE 4160-01-P


